<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043888</url>
  </required_header>
  <id_info>
    <org_study_id>AZL30006</org_study_id>
    <nct_id>NCT00043888</nct_id>
  </id_info>
  <brief_title>Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR</brief_title>
  <official_title>A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg Twice Daily or 700mg/100mg Twice Daily) When Used in Combination With a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR Twice Daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Antiretroviral Therapy (ART) naive subjects will be enrolled in this clinical research study&#xD;
      to test the safety and tolerability of fosamprenavir with or without ritonavir in combination&#xD;
      TRIZIVIR and COMBIVIR. Subjects will receive 24 weeks of therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the overall short term tolerance of the regimens under investigation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nature and incidence of laboratory abnormality; impact/burden of adverse events to subjects; plasma zidovudine (ZDV)pharmacokinetic parameters; change from baseline in plasma HIV-1 RNA levels over time.</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fosamprenavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COMBIVIR</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRIZIVIR</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Lab result for Screening viral load (HIV-1 RNA) greater than or equal to 1,000 copies&#xD;
             per mL.&#xD;
&#xD;
          -  Lab result for Screening CD4 cell count greater than or equal to 100 cells per&#xD;
             microliter.&#xD;
&#xD;
          -  Antiretroviral therapy naive (no prior therapy allowed).&#xD;
&#xD;
          -  Male or female 13 years of age or older (or 18 years of age or older according to&#xD;
             local requirements).&#xD;
&#xD;
          -  Female subjects must be of non-child bearing potential (i.e. physiologically incapable&#xD;
             of becoming pregnant, including women who are post-menopausal) or of child-bearing&#xD;
             potential with a negative blood pregnancy test at screen and who agree to use a proven&#xD;
             barrier method of contraception (e.g. spermicide plus condom) during the study period.&#xD;
             Hormonal contraceptives will not be considered sufficient forms of contraception for&#xD;
             this study. All subjects participating in this study should be counselled on the&#xD;
             practice of safe or safer sex.&#xD;
&#xD;
          -  Able to understand and provide written informed consent to participate in this trial.&#xD;
             Parental or guardian consent must also be obtained for subjects under the age of 18&#xD;
             years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of having received antiretroviral therapy.&#xD;
&#xD;
          -  An active HIV Associated Disease (Center for Disease Control Category C) within 28&#xD;
             days of study drug administration.&#xD;
&#xD;
          -  Any sudden onset or sharp rise in a laboratory abnormality (including abnormally high&#xD;
             laboratory values) at Screening that causes the investigator to have the opinion that&#xD;
             the subject should not participate in the study of an investigational compound.&#xD;
&#xD;
          -  Subjects with a laboratory result for estimated creatinine clearance less than 40 ml&#xD;
             per minute within 28 days of study drug administration.&#xD;
&#xD;
          -  Laboratory result for serum aminotransferase (AST, ALT) levels elevated greater than&#xD;
             five to ten times (or more) the upper limit of the normal range within 28 days prior&#xD;
             to study drug administration.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  History of clinically relevant pancreatitis or hepatitis within 6 months of study drug&#xD;
             administration.&#xD;
&#xD;
          -  Presence of any serious medical condition (e.g., diabetes, cardiac dysfunction,&#xD;
             hepatitis) which, in the opinion of the investigator, might compromise the safety of&#xD;
             the subject.&#xD;
&#xD;
          -  Presence of a malabsorption syndrome or other gastrointestinal dysfunction which might&#xD;
             interfere with drug absorption or render the subject unable to take oral medication.&#xD;
&#xD;
          -  History of a drug or other allergy which, in the opinion of the investigator,&#xD;
             contraindicates the subject's participation in the study.&#xD;
&#xD;
          -  Treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days&#xD;
             of study drug administration or anticipated need for such treatment during the study.&#xD;
&#xD;
          -  Treatment with immunomodulating agents (such as systemic corticosteroids,&#xD;
             interleukins, interferons) or any agent with known anti-HIV activity (such as&#xD;
             hydroxyurea or foscarnet) within 28 days of study drug administration.&#xD;
&#xD;
          -  Treatment with any HIV vaccine within 3 months of study drug administration.&#xD;
&#xD;
          -  Treatment with other selected medications within 28 days prior to receiving study&#xD;
             medication or the anticipated need during the study.&#xD;
&#xD;
          -  Current alcohol or illicit drug use which, in the opinion of the investigator, may&#xD;
             interfere with the subject's ability to comply with the requirements of the study.&#xD;
             Note: Subjects stabilized on methadone can be considered for participation.&#xD;
&#xD;
          -  Treatment with other investigational drugs or therapies within 28 days prior to Day 1,&#xD;
             or an anticipated need for such treatment during the study. Treatments available&#xD;
             through a Treatment IND or other expanded-access mechanism will be evaluated on a&#xD;
             case-by-case basis.&#xD;
&#xD;
          -  Other inclusion or exclusion criteria to be determined by the investigator and sponsor&#xD;
             of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trial, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Manchester</city>
        <zip>M8 6RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>August 14, 2002</study_first_submitted>
  <study_first_submitted_qc>August 16, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2002</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <keyword>fosamprenavir</keyword>
  <keyword>ritonavir</keyword>
  <keyword>COMBIVIR</keyword>
  <keyword>TRIZIVIR</keyword>
  <keyword>abacavir</keyword>
  <keyword>lamivudine</keyword>
  <keyword>zidovudine</keyword>
  <keyword>HIV</keyword>
  <keyword>protease inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

